- 18
- 10 670
Impatient Health
United Kingdom
Приєднався 3 тра 2021
Patients need better. And we can do better.
Led by Paul Simms, Impatient Health is primarily a mix of think tank and consultancy - delivering insights and new designs for the future of life sciences. We believe pharma is a young industry, with much unexplored potential for improved health outcomes. Our aim is to make us more creative and more ambitious.
Led by Paul Simms, Impatient Health is primarily a mix of think tank and consultancy - delivering insights and new designs for the future of life sciences. We believe pharma is a young industry, with much unexplored potential for improved health outcomes. Our aim is to make us more creative and more ambitious.
Redefining content standards with technology
How AI and human combinations are reshaping content excellence
Переглядів: 13
Відео
OMNICHANNEL ALCHEMY | Webinar
Переглядів 2314 днів тому
Turn a great launch party into a sustained success!
Next-Generation Healthcare Interactions
Переглядів 14921 день тому
Harness compliant conversational AI agents and two-way interactions to enhance both HCP and internal team performance
The real cost of MLR
Переглядів 229Місяць тому
Understand and overcome the failures of in-house review and fragmented processes in medical affairs.
Reach every HCP, Realise every opportunity
Переглядів 101Місяць тому
How a smarter digital approach can enhance accessibility and redefine medical engagement
Enhanced Engagement
Переглядів 117Місяць тому
The science and strategy of using AI to boost field performance
Silos to Synergy
Переглядів 1312 місяці тому
Harness technology to integrate pharma teams and optimize operational processes
From Insights to Impact
Переглядів 973 місяці тому
Empowering medical and commercial to drive internal influence and real change
The Patient Pivot
Переглядів 26210 місяців тому
Once upon a time, engaging patients was a one-off, tick-box exercise: “Have you engaged with patients?” “Yes, I spoke to them 6 months ago.” Oh dear. That’s obviously not good enough. We are slowly evolving to involve and include patients through multiple touchpoints, and some of us can even say we are co-creating. But still, we can do better. We can leapfrog and get further ahead. Patient enga...
MUSK PHARMA
Переглядів 3,6 тис.11 місяців тому
Just imagine. Elon Musk at the helm of a pharma company. Some of us would run a mile; some would have renewed hope for the shakeup of a stale and conservative sector. Welcome to a thought experiment, diving into unconventional ways of doing business. This whitepaper scrutinises Musk's radical approach, blending audacity with pragmatism, challenging the cautious pace of industry innovation. Prep...
Pharma's Burning Platform | Webinar Recording
Переглядів 353Рік тому
A webinar from Impatient Health, recorded on 7th July 2023. Featuring Paul Simms, Noreen Sajwani, Ester Banque and Jacob LaPorte. Find more details here: www.impatient.health/webinars/webinar34/
What is the Impatient Innovation Process? | Pharmageddon Short
Переглядів 362Рік тому
Noreen Sajwani, Impatient Health's Head of Consulting, answers questions on how our Innovation Process informs our work and what you'll learn at Pharmageddon this October. Find out more about Pharmageddon at www.impatient.health/our-events/pharmageddon1/. Interviewed by Alex Norman, Head of Commercial Strategy at Impatient Health.
Welcome to Pharmageddon | Impatient Health
Переглядів 913Рік тому
Imagine an event which does away with the exhibition room. Imagine building something with your peers instead of just listening to them. Imagine stretching yourself to work on future challenges outside your comfort zone, instead of discussing the past. This is all possible. This is Pharmageddon. Click here to learn more: www.impatient.health/PG
An Apple a Day... | From Predictions 2023
Переглядів 239Рік тому
This is an excerpt of Prediction 3, 'An Apple a Day Keeps the Doctor... Closer', from Impatient Health's annual Predictions webinar, broadcast on 4 January 2023 and hosted by Paul Simms and Noreen Sajwani. If you enjoyed this prediction, you might be interested in Pharmageddon 2023, a brand new event hosted by Impatient Health in Barcelona this May. Find out more at impatient.health/our-events/...
The Bonfire of Big Pharma | From Predictions 2023
Переглядів 279Рік тому
This is an extract from Impatient Health's annual Predictions webinar, broadcast on 4 January 2023 and hosted by Paul Simms and Noreen Sajwani. If you enjoyed this prediction, you might be interested in Pharmageddon 2023, a brand new event hosted by Impatient Health in Barcelona this May. Find out more at www.impatient.health/our-events/pharmageddon1/. You can learn more about Impatient Health ...
Predictions 2023 with Paul Simms | Impatient Health
Переглядів 1,6 тис.Рік тому
Predictions 2023 with Paul Simms | Impatient Health
Predictions with Paul Simms 2022 (live session)
Переглядів 1,1 тис.2 роки тому
Predictions with Paul Simms 2022 (live session)
PSI is not a CRO FYI
Not only are we not doing enough, I think it is time to think beyond engagement (a word that has been mangled by the healthcare industry) and shoot for activation; It ain't dog food if the dog don't eat it. That means we need to think about people involved in health and care as people, not patients. It also likely requires all content and support being delivered in a contextual way based on 'segments of one'.
Wonderful session! Thanks for doing this
...
So Pharma needs a hype man? Looking at the results from your first poll at the beginning, I can see that pharma workers have learned the wrong lesson from Theranos.
The record of the tech world entering and disrupting health care is not good. I suspect Apple will be no different.
Well done. Great thinking.
I think no. 4 on the 2022 list gets partial credit given the dip in Lilly’s stock after the fake twitter account and its free insulin tweet
Insightful, informative and upbeat, looking up Prof Brian Smith now, thank you
Prediction 5 "The beginning of the end for commercial teams in pharma" is an interesting one. There seems to be a gap still between what HCPs say and what they do and that continues to allow pharma companies to continue as is. Your follow up slide pretty much showed that plenty of sales teams will be wanting to get back to face to face like nothing every changed.
excellent viewing, thought-provoking, and well thought out, thank you, Paul